Abingworth LLP Hille Vax, Inc. Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
A detailed history of Abingworth LLP transactions in Hille Vax, Inc. stock. As of the latest transaction made, Abingworth LLP holds 1,838,486 shares of HLVX stock, worth $22.3 Million. This represents 10.2% of its overall portfolio holdings.
Number of Shares
1,838,486
Previous 1,838,486
-0.0%
Holding current value
$22.3 Million
Previous $31.4 Million
2.05%
% of portfolio
10.2%
Previous 10.74%
Shares
1 transactions
Others Institutions Holding HLVX
# of Institutions
82Shares Held
39MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.78MShares$119 Million8.54% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$48.6 Million1.38% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.06MShares$37.2 Million0.03% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.57MShares$31.2 Million1.41% of portfolio
-
Vr Adviser, LLC New York, NY2.08MShares$25.2 Million2.96% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $406M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.